Colorectal Cancer Patient Survival Data with ANLR Biomarker

A retrospective cohort study analyzes 1,436 colorectal cancer patients who underwent surgical resection between 2015 and 2017. The research investigates the prognostic value of the Albumin/Neutrophil-to-Lymphocyte Ratio (ANLR) for progression-free and overall survival, with a median follow-up of 65 months. It includes statistical models and nomograms predicting 1-, 3-, and 5-year survival rates.

Use Cases

• Analyze the association between the ANLR biomarker and progression-free survival (PFS) outcomes using Cox regression models.
• Investigate the independent relationship of ANLR with sarcopenia risk through logistic regression analysis.
• Validate the clinical utility of ANLR-based nomograms for predicting 1-, 3-, and 5-year overall survival (OS) rates against traditional TNM staging.
• Assess the correlation between high ANLR values and reduced risk of postoperative complications.

Strengths

• Study includes 1,436 patient records from a defined cohort.
• Data has a median follow-up duration of 65 months for longitudinal survival analysis.
• Analysis provides specific hazard ratios (e.g., HR=0.745 for PFS) and odds ratios (e.g., OR=0.593 for sarcopenia) for key relationships.

Limitations

• Dataset is a 72.1 KB document; the underlying tabular patient data is not directly accessible.
• Study is from a single institution, which may limit generalizability.
• Temporal coverage is limited to patients treated between 2015 and 2017.

Provenance

Source

figshare, authored by Hailun Xie.

Collection Method

Retrospective cohort study of patients who underwent surgical resection.

Time Range

Patient treatment between 2015 and 2017, with follow-up.

Freshness

null

Geography

Single institution; specific location unknown.